Philip J. Mease
YOU?
Author Swipe
View article: Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials Open
ClinicalTrials.gov identifier NCT03162796, NCT03158285, NCT03796858.
View article: Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Open
ClinicalTrials.gov identifier, NCT05195814.
View article: Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors Open
This real-world study identified greater on-label treatment persistence rates at 24 months in patients with active PsA initiating guselkumab versus SC IL-17Ai, overall and among biologic-naïve and biologic-experienced subgroups.
View article: On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors Open
Patients with active PsA initiating guselkumab were significantly (approximately two times) more likely to remain persistent with on-label therapy through 24 months versus SC TNFi, overall and among biologic-naïve and biologic-experienced …
View article: Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial Open
Psoriatic arthritis (PsA) is a progressive, multidomain and interleukin-17 (IL-17)-linked disease that results in substantial quality-of-life deficits. Thereby, we conducted a phase 2 randomized, double-blind, placebo (PBO)-controlled tria…
View article: Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis Open
Background Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (…
View article: Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies Open
Objective To assess the long-term effect of bimekizumab, a dual inhibitor of IL-17A and IL-17F, on patient-reported symptoms, function and health-related quality of life (HRQoL) in patients with axial spondyloarthritis (axSpA) from phase 3…
View article: Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study Open
Guselkumab, a fully human monoclonal antibody able to bind CD64 and simultaneously inhibit the IL-23p19 subunit, provided significantly higher rates of clinical improvement and significant inhibition of structural damage progression versus…
View article: Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The <scp>CorEvitas</scp> Psoriatic Arthritis/Spondyloarthritis Registry
Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The <span>CorEvitas</span> Psoriatic Arthritis/Spondyloarthritis Registry Open
Objective Our objective was to describe characteristics and compare clinical and patient‐reported outcomes (PROs) for disease‐modifying antirheumatic drug (DMARD)–naive patients with psoriatic arthritis (PsA) who initiate DMARD therapy ear…
View article: Candidate Instruments for Central, Non-Inflammatory, and Nociplastic Pain Assessment in Inflammatory Arthropathies: An OMERACT Scoping Review Protocol
Candidate Instruments for Central, Non-Inflammatory, and Nociplastic Pain Assessment in Inflammatory Arthropathies: An OMERACT Scoping Review Protocol Open
IntroductionNociplastic pain is an important mechanistic pain descriptor that plays a significant role in influencing reported pain intensity and complicating outcome assessment in inflammatory arthropathies (IA). This pain is not driven b…
View article: Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies Open
This Summary of Research summarises results from the BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) studies and their open-label extension, BE VITAL (NCT04009499). These phase 3 studies looked at how well bimekizumab treatment work…
View article: Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study Open
Izokibep resulted in significant and clinically meaningful improvements over placebo across multiple disease domains, and the originally randomised 80-mg dose showed continued improvements to week 46. There were no unexpected safety risks …
View article: P165 Bimekizumab impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) core domains for patients with psoriatic arthritis: results up to 2 years of treatment duration
P165 Bimekizumab impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) core domains for patients with psoriatic arthritis: results up to 2 years of treatment duration Open
Background/Aims The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domainbased treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial disease, enthesitis, dactylitis, skin psoriasis, nail p…
View article: Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies Open
Objective To assess the long-term safety profile of bimekizumab (BKZ) in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Methods Safety data pooled from six integrated phase IIb/III studies in axSpA and PsA are…
View article: P177 Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies
P177 Updated long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies Open
Background/Aims Updated pooled safety data are presented to July 2023, across integrated phase 2b/3 studies of bimekizumab (BKZ) in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients. Methods Safety data are reported fo…
View article: P190 An international modified Delphi study to understand clinical opinion on current and potential future use of Janus kinase inhibitors in rheumatic and musculoskeletal diseases: global results
P190 An international modified Delphi study to understand clinical opinion on current and potential future use of Janus kinase inhibitors in rheumatic and musculoskeletal diseases: global results Open
Background/Aims Janus kinase inhibitors (JAKi) have proven effective for many rheumatic and musculoskeletal diseases (RMDs). Enriched treatment experience for established indications, case reports highlighting broader use and the availabil…
View article: P174 Bimekizumab-treated patients with active psoriatic arthritis showed sustained improvements in pain and fatigue: up to 2-year results from two Phase 3 studies
P174 Bimekizumab-treated patients with active psoriatic arthritis showed sustained improvements in pain and fatigue: up to 2-year results from two Phase 3 studies Open
Background/Aims Bimekizumab (BKZ) has demonstrated sustained improvements in pain and fatigue to 1 year in patients with active PsA. Here, we report assessments of patien-treported pain and fatigue up to 2 years in BKZ-treated PsA patients…
View article: Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis
Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis Open
Objective We aimed to assess differences in baseline characteristics, efficacy, and safety of advanced therapies between male and female patients with axial spondyloarthritis (axSpA) in randomized controlled trials (RCTs). Methods We condu…
View article: Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies
Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies Open
Objective To assess the longer-term effect of bimekizumab up to 1 year on patient-reported symptoms, health-related quality of life (HRQOL), and work productivity in patients with active PsA who were biologic disease-modifying antirheumati…